Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces that Karen Chagin, MD has joined the Company as its Senior Vice President of Early-Stage Development. Dr. Chagin will oversee the Company's early-stage pipeline activities from pre-IND and IND activities through Phase 1 clinical trials.
Karen joins Adaptimmune from Tmunity where she served as Chief Medical Officer and previously as Head of Clinical Development and Clinical Operations. She led and was accountable for the development strategy, planning, and execution of Tmunity's CAR T-cell therapies in multiple solid tumor types. She subsequently became the Head of Kite Philadelphia following Kite's acquisition of Tmunity.
Prior to Tmunity, Dr. Chagin worked at Adaptimmune from 2015 to 2019 serving as Vice President of Clinical Development and she was the clinical lead for the afami-cel and lete-cel programs.
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "Karen brings extensive oncology and cell therapy development leadership expertise to Adaptimmune. She has spent nearly a decade building solid tumor cell therapy programs from IND into late-stage clinical development. We are thrilled that she will lead the development of our next wave of cell therapies for solid tumors."
Karen Chagin, Adaptimmune's Senior Vice President of Early-Stage Development: "Adaptimmune's cell therapies for cancer have tremendous potential and we are on the cusp of bringing our first product, afami-cel, to market. I was here for the early days of afami-cel, and I am eager to advance our other cell therapies through early-stage development."
Prior her first role at Adaptimmune, Dr. Chagin served as a Scientific Director in Oncology Early Development at Janssen leading development activities for Phase 1 assets. Dr. Chagin began her career in the pharmaceutical industry in 2009 at GSK and served as a Safety Development leader. She managed clinical safety for multiple early and late-stage products and was the Chair of the Hematology Safety Panel prior to transitioning to clinical development. As a Medical Director for Promacta®/Revolade®, Dr. Chagin was responsible for the development and execution of multiple Phase 2 and 3 clinical trials. In her roles in safety and clinical development, Dr. Chagin led and contributed to the registration of several products and indications globally.
Dr. Chagin holds a B.A. from the University of Pennsylvania and an M.D. from Temple University School of Medicine. She performed her residency at Children's Memorial Hospital in Chicago and her fellowship in pediatric hematology and oncology at The Children's Hospital of Philadelphia.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's cell therapy products have shown clinical responses in multiple solid tumor indications. Our unique T-cell platforms enable us to identify cancer targets, find and develop cell therapy candidates active against those targets, and produce therapeutic candidates for administration to patients. Adaptimmune's cell therapy products include T-cells with genetically engineered T-cell receptors ("TCR T-cells"), TCR Fusion Construct T cells (TRuC-T cells), and HLA-independent TCRs ("HiTs").
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC) on March 6, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts:
Investor Relations
Juli P. Miller, Ph.D., VP of Corporate Affairs and Investor Relations
M: +1 215 460 8920
Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/179900
